Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACCELERON PHARMA INC.

(XLRN)
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Acceleron Pharma : Holocene Advisors says Merck's offer undervalues Acceleron

10/13/2021 | 03:40pm EST

Oct 13 (Reuters) - Investment management firm Holocene Advisors said on Wednesday that Merck & Co's proposed offer of $180 per share for Acceleron Pharma Inc significantly undervalues the company.

Holocene Advisors is a shareholder in Acceleron. (Reporting by Praveen Paramasivam in Bengaluru)


ę Reuters 2021
All news about ACCELERON PHARMA INC.
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Biotechnology Index
CI
11/22ACCELERON PHARMA : Completion of Acquisition or Disposition of Assets - Form 8-K
PU
11/22ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delis..
AQ
11/22Merck Completes Acceleron Pharma Acquisition
MT
11/22Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
AQ
11/22Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share
MT
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from NASDAQ Composite Index
CI
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Global BMI Index
CI
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P TMI Index
CI
11/22ACCELERON PHARMA INC.(NASDAQGM : XLRN) dropped from S&P Biotechnology Select Industry Inde..
CI
More news
Analyst Recommendations on ACCELERON PHARMA INC.
More recommendations
Financials (USD)
Sales 2021
Net income 2021
Net Debt 2021
P/E ratio 2021
Yield 2021
Capitalization 10 932 M 10 932 M -
EV / Sales 2021
EV / Sales 2022 52,9x
Nbr of Employees 312
Free-Float 88,0%
Chart ACCELERON PHARMA INC.
Duration : Period :
Acceleron Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCELERON PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Habib J. Dable President, Chief Executive Officer & Director
Kevin F. McLaughlin Chief Financial Officer, Treasurer & Senior VP
Francois Nader Non-Executive Chairman
Ravindra Kumar Chief Scientific Officer & Senior Vice President
Jay T. Backstrom Executive VP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ACCELERON PHARMA INC.39.71%10 932
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678